Type Whole antibody Target BAFF CAS Number 1143503-67-6 | Source Human ATC code none ChemSpider none | |
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.
References
Tabalumab Wikipedia(Text) CC BY-SA